Main Article Content
Uterine fibroids, also known as uterine Leiomyomas or fibroids, are benign smooth muscle tumours of the uterus that can be seen in women of child bearing age. Women in their first trimester of pregnancy suffer no symptoms, but others may experience painful or heavy periods. The presence of fibroids might occasionally make it more difficult to become pregnant; however, this is uncommon. Approximately 20 percent to 80 percent of women develop fibroids by the time they reach the age of 50. If there are no symptoms, it is typically not necessary to seek medical attention. Paracetamol (acetaminophen) and other nonsteroidal anti-inflammatory medicines (NSAIDs) may be used to relieve pain and bleeding, while ibuprofen and other NSAIDs may be used to relieve pain and bleeding. It is possible that women who have heavy periods will require iron supplements. The use of medications from the gonadotropin-releasing hormone agonist family may help to reduce the growth of fibroids, but they are both expensive and associated with negative side effects. Patient counselling and education will aid in lowering the risk to patients and slowing the progression of the study. The work done to determine the causes of anaemia will aid in increasing knowledge about anaemia, including dietary modifications, and decreasing the progression of the study by providing patient counselling and education. The findings of a six month study of 75 cases of fibroids discovered in 362 samples revealed that uterine fibroids are the most common malignancy in women of reproductive age. Uterine fibroids are not only found in women of null parity; they can also be found in women with multiple pregnancies. On the contrary, the prevalence of anaemia, heavy bleeding with clots, and metrorrhagia in fibroids is rather high, which has an impact on psychological state as a result of the stigma associated with the sickness status, and which interferes with everyday activities.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.